Bristol-Myers Squibb Company, a New York-based pharmaceutical company, has issued $19 billion in senior notes.
This included the issue of $750 million floating-rate notes due 2020, $500 million floating-rate notes due 2022, $1 billion 2.55% notes due 2021, $1.5 billion 2.6% notes due 2022, $3.25 billion 2.9% notes due 2024, $2.25 billion 3.2% notes due 2026, $4 billion 3.4% notes due 2029, $2 billion 4.125% notes due 2039 and $3.75 billion 4.25% notes due 2049.
The company plans to use the proceeds from the notes issue to partially finance its proposed acquisition of Celgene Corporation.